Carcinoembryonic antigen in osteosarcoma

Area of Science:

• Oncology
• Biomarkers
• Cancer Research

Background:

• Osteosarcoma is a primary bone malignancy.
• Accurate monitoring of treatment response is crucial for patient outcomes.
• Carcinoembryonic antigen (CEA) is a tumor marker with potential utility in various cancers.

Purpose of the Study:

• To evaluate the diagnostic and prognostic value of plasma carcinoembryonic antigen (CEA) assay in patients with osteosarcoma.
• To assess the correlation between CEA levels and disease status (active disease vs. remission).
• To determine the utility of serial CEA monitoring in predicting treatment response and recurrence.

Main Methods:

• Plasma CEA levels were measured in 30 patients diagnosed with osteosarcoma.
• CEA levels were analyzed in relation to active disease, complete remission, and treatment interventions (surgery, chemotherapy).
• Serial CEA determinations were performed to track changes during therapy and identify potential recurrence.

Main Results:

• CEA was positive (>2.5 ng/ml) in 17 out of 21 patients with active osteosarcoma.
• CEA was negative (<2.5 ng/ml) in all 9 patients in complete remission.
• Successful treatment led to normalized CEA levels in 7 out of 9 patients.
• Fluctuating CEA levels were observed in 8 patients with tumor progression during chemotherapy.
• Clinical recurrence preceded or coincided with CEA elevation in two instances.

Conclusions:

• Plasma CEA assay is a valuable adjunct in monitoring osteosarcoma patients, complementing clinical judgment and imaging.
• Serial CEA monitoring can aid in prognostication, reflecting treatment efficacy and disease progression.
• While non-specific, CEA trends provide important insights into osteosarcoma course, but interpretation requires caution.